Regardless of interval or dose level, both heterologous and homologous Ad26, MVA Ebola vaccine regimens were observed to be well tolerated in healthy adults.
Atoltivimab, maftivimab, and odesivimab-ebgn is a combination of Zaire ebolavirusglycoprotein directed recombinant human IgG1 human monoclonal antibodies.
Current WHO Ebola case definitions perform suboptimally at case identification in both community and clinical triage settings.
A glycoprotein in Ebola called the mucin-like domain may be of interest in the development of an oncolytic for brain cancer.
Data from a large sample of Ebola survivors confirmed the persistence of Ebola viral RNA in semen for up to 6 months.
The FDA has approved Ervebo (Ebola Zaire vaccine, live) for the prevention of disease caused by Zaire ebolavirus in individuals ≥18 years of age.
The world’s first Ebola vaccine has been approved by the European Commission, and it was quickly prequalified by the World Health Organization.
New drugs cured two Ebola patients in Congo, showing that people can recover from the highly lethal disease if it is diagnosed and treated early.
The first transmission of the Ebola virus in Congo’s major city of Goma was announced.
The first case of Ebola in the city of Goma has been confirmed, Democratic Republic of Congo officials said Sunday.
Agency says outbreak is an ‘extraordinary event’ of deep concern but not a global emergency
The United States is stepping up its response to a historic outbreak of Ebola in two African nations.
A recent study examining Ebola virus disease survival and intravenous fluid administration brings to light broader knowledge gaps about survival management that should be studied further.
A single monoclonal antibody, mAb114, targeting the receptor-binding domain of Ebola virus glycoprotein showed linear pharmacokinetics and was easily and rapidly infused.
The ongoing Ebola outbreak in the Democratic Republic of Congo has claimed the lives of nearly 100 children, and the number of cases are on the rise.
Patient completed required 21-day monitoring period and did not develop any symptoms.
So far, the American has not shown any symptoms of infection from the virus.
The immunogenicity generated by 3 experimental Ebola vaccines appears to be long-lasting, as it has persisted for at least 2.5 years.
A simple intradermalanti-Ebola DNA vaccine may generate strong immunogenicity and induce long-term immune responses in nonhuman primates.
Ebola infections in newborns are being reported in the current outbreak of the deadly disease in Congo.